Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical COVID‐19 pneumonia: A double‐blind randomized, placebo‐controlled clinical trial

Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical COVID‐19 pneumonia: A double‐blind randomized, placebo‐controlled clinical trial

Abstract Introduction Selective serotonin reuptake inhibitors are considered the drugs, whose effectiveness in viral pandemics has been studied. The aim of this study was to evaluate of adding fluoxetine to the treatment regimen of patients with COVID‐19 pneumonia. Methods This study was a double‐bl...

Full description

Bibliographic Details
Main Authors: Faranak Sedighi, Mehran Zarghami, Fatemeh Alizadeh Arimi, Mahmood Moosazadeh, Shahram Ala, Roya Ghasemian, Hossein Mehravaran, Forouzan Elyasi
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Neuropsychopharmacology Reports
Subjects:
anxiety
COVID‐19
depression
drug regimens
fluoxetine
Online Access:https://doi.org/10.1002/npr2.12327

Internet

https://doi.org/10.1002/npr2.12327

Similar Items